IWY357

Novartis
Asexual blood stages

IWY357

Translational
-
Preclinical
Product vision
  • Uncomplicated malaria treatment and resistance management
MOA
  • Novel and unknown
Key features
  • No cross-resistance
  • No resistant mutants identified
  • Low predicted dose (<100 mg) and long predicted half-life in human
  • Fast killing in vitro and in vivo
Challenges
  • Partner drug selection
Status
  • Good Laboratory Practice (GLP) toxicology completed
Next milestone
  • Start of first-in-human phase I clinical study
Project Director
  • Dr Andrew Slade